1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nascent Pharma Holdings, Inc.

Nascent Pharma Holdings, Inc.

NASC
Nascent Pharma Holdings, Inc.US flagOther OTC
0.01
USD
- -
- -
985,946.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
0.06
0.62
0.41
0.54
2.31
2.94
3.34
10.9
16.8
7.26
3.43
1.87
0.17
0.02
Basic EPS, GAAP
-32.67
-42.71
-8.13
-0.67
-75.29
-20.55
-58.28
-67.05
-43
-37.68
-9.06
-4.18
-0.77
-0.25
Free Cash Flow per Basic Share
-11.29
-14.54
-9.79
-0.66
-7.47
-4.4
-7.8
-13.8
-29.65
-8.48
-6.09
-1.11
-0.1
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-165.89
-192.97
-190.73
-208.44
-248.25
-386.41
-57.84
-34.96
-2.52
-147.35
-20.91
-3.63
-1.51
-0.55
Tangible Book Value per Share
33.38
0.78
1.46
0.4
-0.63
-19.89
-53.76
-18.34
-2.08
-138.22
-17.42
-1.58
-0.74
-0.34
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
4
13
52
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
1
2
2
5
7
2
1
Operating Margin (%)
-55,344.85
-6,840.91
-1,921.11
90.88
-1,280.44
-432.55
-580.7
-510.88
-255.58
-440.83
-222.99
-211.92
-347.28
-731.84
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Net Income, GAAP
-1
-2
- -
- -
-4
-1
-2
-4
-6
-9
-12
-15
-10
-13
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-55,612.72
-6,885.22
-1,959.51
-125.7
-3,252.46
-698.99
-1,743.21
-615.06
-255.94
-519.33
-264.33
-223.23
-451.7
-1,282.82
Working Capital
- -
- -
- -
- -
- -
-1
-2
1
3
1
-3
-4
-6
-10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
Total Equity
1
- -
- -
- -
- -
-1
-2
3
7
1
6
3
-1
-10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
8
8
9
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
8
8
8
Shares Outstanding
45
62
70
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
4
4
2
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
4
3
1
Inventories
1
1
- -
Total Current Liabilities
10
11
12
Payables & Accruals
2
3
3
ST Debt
8
8
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-18.99%
20.88%
-137.14%
Free Cash Flow
192.65%
104.25%
-66.57%
Net Income, GAAP
1,364.11%
23.78%
-34.75%
Sales/Revenue/Turnover
127.62%
73.14%
-67.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
2
1
3
1
7
2023
1
- -
- -
- -
2
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-1.1
-0.49
-1.98
- -
-4.18
2023
-0.36
-0.37
-0.36
- -
-0.77
2024
-0.16
-0.04
-0.05
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Marco Alfonsi
Full Time Employees
12
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
960 South Broadway Hicksville NY United States of America 11801
IPO Date
Aug 3, 2012
CIK
0001509957
Website
nascentpharmaholdings.com
Similar Companies
Kaken Pharmaceutical Co., Ltd. (KKPCF)
Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS)
Adamas Pharmaceuticals, Inc. (ADMS)
iAnthus Capital Holdings, Inc. (ITHUF)
Knight Therapeutics Inc. (GUD.TO)
Alliance Growers Corp. (ALGWF)
Business
I will compile a professional company description based on publicly available information to reflect Nascent Pharma Holdings, Inc. (NASC) and its latest developments.

Company News

APIChatGPT

  • globenewswire.com

    Can B Corp. Announces Holding Company Reorganization With Nascent Pharma Holdings, Inc. to Become the Publicly-Traded Parent Company

  • globenewswire.com

    Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million

  • globenewswire.com

    Can B Corp. Expects Nearly $500,000 Annual Savings With Successful Completion of Move of Pure Health Products From Lacey, WA to Colorado

  • globenewswire.com

    Can B Corp. Secures 1.8 Million Pounds of Biomass for Awarded Contract With One Bad Moon Rising

  • accesswire.com

    Can B Corp. Secures Lease for 300,000 Square Foot Facility in McMinnville, Tennessee

  • globenewswire.com

    Can B Corp. Strengthens Its Vertical Processing Capabilities With Acquisition of Assets From Music City Botanicals

  • accesswire.com

    Can B Corp. Closes Acquisition of Assets from Music City Botanicals to Strengthen its Vertical Processing Capabilities

  • accesswire.com

    Can B Corp. Reports 96% Revenue Growth for Its Second Quarter 2021

  • accesswire.com

    Can B Corp. Closes Acquisition of Assets from TWS Pharma in CO to Significantly Expand Capabilities in Converting Hemp Biomass to Isolate Used in our CBD and Isomer Product Lines

  • accesswire.com

    Can B Corp Announces First Quarter 2021 Results

  • accesswire.com

    Can B Corp. Enters the Industrial Hemp Business

  • accesswire.com

    Can B Corp. Announces Full Year 2020 Results

  • accesswire.com

    Can B Corp. to Present at Virtual Investor Summit on March 23, 2021 at 3:00 PM ET

  • accesswire.com

    Can B Corp. Acquires Assets from Leading-Edge Hemp Technology Group

  • globenewswire.com

    Can B Corp Partners with Signature PR to Launch a New Premier Line

  • globenewswire.com

    Can B Corp. Accelerates its Innovations and Advancements at Pure Health Products

  • globenewswire.com

    Can B Corp and Dr. Karl Zarse Launch ImmuneX2